ClinicalTrials.gg
RecruitingNCT07718165Updated Sep 4, 2026

A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration

A Phase 1 interventional study of ABSK211 in Solid Tumor (Phase I), sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
247
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.

Read the detailed description

The study will start with a dose escalation of oral ABSK211 in participants with advanced solid tumors with KRAS alteration to evaluate safety, tolerability, and PK. The expansion part will evaluate the safety and efficacy of oral ABSK211 at the recommended doses for expansion (RDEs) in selected tumor types harboring KRAS alteration and further optimize the dosage.

02

Conditions studied

  • Solid Tumor (Phase I)

Keywords

  • ABSK211, KRAS Alteration
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Participants should understand, sign, and date the written form prior to screening.
  2. Male or female age 18 years or older
  3. Participants with confirmed locally-advanced or solid tumors harboring KRAS alteration
  4. performance status 0 or 1
  5. ≥ 3 months
  6. Adequate organ function and bone marrow function
  7. For participants participating exploration of food effect:

1)be able to eat a standardized high-fat, high caloric meal within 30 minutes. 2) be able to fast for 10 hours.

Exclusion Criteria:

  1. Known allergy or to any component of the product
  2. Participants who were previously treated with any inhibitors targeting specific KRAS alleles, pan-KRAS inhibitors, pan- or multi-RAS inhibitors, or any other treatments directly targeting RAS.
  3. Has a known additional that is progressing or has required active treatment
  4. Has swallowing dysfunction or malabsorption syndrome
  5. Previous anti-tumor therapy, including chemotherapy ,endocrine therapy, molecular targeted therapy or other investigational drugs received ≤2 weeks or ≤5-half life ,radiotherapy and antibody therapy received ≤4 weeks prior to initiation of study treatment.
  6. Major surgery within 4 weeks of the first dose of investigational product or with any unhealed surgical wounds, infection or dehiscence.
  7. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy, that have not regressed to Grade ≤1 severity;
  8. Participants use proton pump inhibitors for at least 7 days prior to the first dose of ABSK211 and during treatment with ABSK211.
  9. P-gp inhibitor, moderate and strong inhibitors to 7 days or 5 half-lives and for strong CYP3A inducers to 2 weeks or 5 half-lives ;
  10. Active central nervous system (CNS) metastases;
  11. History of interstitial lung disease (ILD) requiring systemic treatment;
  12. Heart disease or medical history ;
  13. NSCLC cohorts: Participant previously identified as having a driver mutation and have not received any targeted therapy;
  14. Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for 1/2 antibody;
  15. Exclusion of hepatitis infection;
  16. Participants with /uncontrolled ascites or pleural effusion;
  17. Pregnant or nursing (lactating) women;
  18. Partners of non-surgically sterilized male participants or female participants of who refuse to use effective methods of during the study and for up to 6 months after the last dose of investigational product;
  19. Sexually active males who refuse to use a condom during medication period and until 3 months after stopping investigational product;
  20. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines ;
  21. Any other comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition;

    -

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
247 participants (estimated)

Study arms

  • Experimental
    ABSK211

    During the escalation part ,all participants will firstly receive a single dose of ABSK211 as a run-in period to access the safety and PK of ABSK211. Then, participants will continuously receive ABSK211 once daily (QD), with each treatment cycle of 21 days; In the expansion part,participants will orally receive ABSK211 at the recommended dose for expansion (RDE).

    Drug: ABSK211

Interventions

  • DrugABSK211

    During the escalation part ,all participants will firstly receive a single dose of ABSK211 as a run-in period to access the safety and PK of ABSK211. Then, participants will continuously receive ABSK211 once daily (QD), with each treatment cycle of 21 days; In the expansion part,participants will orally receive ABSK211 at the recommended dose for expansion (RDE).

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    dose-limiting toxicities

    Time frame: from Run-in to Day21

  2. AEs

    Adverse events

    Time frame: The date of signing the informed consent form until 30 days (including Day 30) after the last administration of investigational product

  3. SAEs

    Serious adverse events (SAEs)

    Time frame: The date of signing the informed consent form until 30 days (including Day 30) after the last administration of investigational product

Secondary outcomes

  1. Cmax

    maximum observed concentration

    Time frame: from pre-dose to up to 72 hours post-dose

  2. Tmax

    time to maximum observed concentration

    Time frame: from pre-dose to up to 72 hours post-dose

  3. AUC

    area under the concentration-time curve

    Time frame: from pre-dose to up to 72 hours post-dose

  4. t1/2

    elimination half-life

    Time frame: from pre-dose to up to 72 hours post-dose

  5. CL/F

    apparent oral clearance

    Time frame: from pre-dose to up to 72 hours post-dose

  6. ORR

    Objective response rate

    Time frame: throughout study completion, assessed up to 24 months

  7. DOR

    Duration of response

    Time frame: throughout study completion, assessed up to 24 months

  8. DCR

    Disease control rate

    Time frame: throughout study completion, assessed up to 24 months

  9. PFS

    Progression-free survival

    Time frame: throughout study completion, assessed up to 24 months

  10. OS

    Overall survival

    Time frame: throughout study completion, assessed up to 24 months

  11. Vz/F

    apparent volume of distribution

    Time frame: from pre-dose to up to 72 hours post-dose

  12. AR

    accumulation ratio

    Time frame: from pre-dose to up to 72 hours post-dose

  13. BPR

    Blood plasma ratio

    Time frame: from pre-dose to up to 72 hours post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2029, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 21, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Dec 30, 2029
CompletionEst.
Jun 30, 2030
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07718165
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Aug 28, 2026
Primary completion
Dec 30, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Sep 4, 2026

Study contacts

Lijun Zheng, Master
Contact
lijun.zheng@abbisko.com
+86-021-68912098
Jiaojuan He, Master
Contact
jiaojuan.he@abbisko.com
+86-18930059542
Xianjun Yu, Doctor
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion